Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 201.99B |
| Revenue (ttm) | 43.89B |
| Net Income (ttm) | 10.86B |
| Shares Out | 1.94B |
| EPS (ttm) | 5.45 |
| PE Ratio | 19.15 |
| Forward PE | 14.69 |
| Dividend | 3.50 (3.35%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 1,531,324 |
| Average Volume | 2,548,249 |
| Open | 103.74 |
| Previous Close | 104.34 |
| Day's Range | 102.60 - 103.92 |
| 52-Week Range | 81.10 - 106.88 |
| Beta | 0.57 |
| RSI | 55.95 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis (NVS) Gains EMA Support for Scemblix in Treating Chronic Myeloid Leukemia
Novartis (NVS) Gains EMA Support for Scemblix in Treating Chronic Myeloid Leukemia
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
Basel, October 17, 2025 – Novartis today announced results from the five-year analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that demonstrated a sustained benefit at a median...
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
Basel, October 17, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended ...
Novartis Reports Positive Fabhalta Results In IgAN
Novartis Reports Positive Fabhalta Results In IgAN
Novartis: Assessing The Impact Of Entresto Generics
Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. Learn more about NVS stock here.
Novartis reports positive data from late-stage trial for Fabhalta
Novartis (NVS) Shows Promising Phase III Results for IgA Nephropathy Treatment
Novartis (NVS) Shows Promising Phase III Results for IgA Nephropathy Treatment
Novartis' Fabhalta slows progression of rare kidney disease in trial
Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta,...
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
Top Stock Reports for SAP, Novartis & Philip Morris
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Novartis (NVO) Streamlines Operations with Layoffs in the US
Novartis (NVO) Streamlines Operations with Layoffs in the US
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
3 Reasons Growth Investors Will Love Novartis (NVS)
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
NVS Named Top 10 SAFE International Dividend Stock
Novartis (Symbol: NVS) has been named to the Dividend Channel ''International S.A.F.E. 10'' list, signifying an international stock with above-average ''DividendRank'' statistics including a strong 3....
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says
GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff ...
Big pharma is at war with the UK, and the government can’t back down now | Nick Dearden
The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain This year so far, some of the biggest pharmaceutical corporations in the worl...
FDA Approves Novartis' Rhapsido As First BTKi Oral Therapy For Chronic Spontaneous Urticaria
(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration has approved Rhapsido (remibrutinib) as an oral treatment for adults with chronic spontaneous urticaria or CSU who conti...
Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment
Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with d...